Clinical Trial Update: DHEA Against Vaginal Atrophy - Safety Study of 12 Months [Phase 3]

View source ↗

Summary

A Phase 3 safety trial evaluating dehydroepiandrosterone (DHEA) for vaginal atrophy has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vaginal Atrophy

Drugs mentioned

• DHEA (dehydroepiandrosterone)

Snippet

Sponsor: EndoCeutics Inc. | Conditions: Vaginal Atrophy | Phase 3 | Status: COMPLETED | Results posted: 2017-10-18